Thalidomide (HAL) maintenance following high-dose melphalan with autologous stem cell transplant (ASCT) for myeloma.

被引：0
|
作者：
Chang, Julie E. [1 ]
Juckett, Mark B. [1 ]
Kahl, Brad. S. [1 ]
Mitchell, Teri L. [1 ]
Gangnon, Ronald E. [1 ]
Callander, Natalie S. [1 ]
Longo, Walter L. [1 ]
机构：
[1] Univ Wisconsin, Dept Hematol & Bone Marrow Transplantat, Madison, WI USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.5455.5455
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5455
引用
收藏
页码：459B / 459B
页数：1
相关论文
共 50 条
  • [21] High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study
    G Meloni
    S Capria
    S Trasarti
    G Ferrazza
    A Micozzi
    MT Petrucci
    F Simone
    SM Trisolini
    F Mandelli
    Bone Marrow Transplantation, 2000, 26 : 1045 - 1049
  • [22] Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).
    Attal, Michel
    Palumbo, Antonio
    Holstein, Sarah A.
    Lauwers-Cances, Valerie
    Petrucci, Maria Teresa
    Richardson, Paul G.
    Hulin, Cyrille
    Tosi, Patrizia
    Anderson, Kenneth Carl
    Caillot, Denis
    Magarotto, Valeria
    Moreau, Philippe
    Marit, Gerald
    Yu, Zhinuan
    McCarthy, Philip L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant
    Radujkovic, Aleksandar
    Hundemer, Michael
    Eisenbach, Christoph
    Luft, Thomas
    Penzel, Roland
    Goldschmidt, Hartmut
    Ho, Anthony D.
    Bellos, Frauke
    LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2967 - 2969
  • [24] Evaluation of High-Dose Melphalan Toxicity by Age in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
    Lea, Julia Cathryn
    Aziz, May
    Simmons, Gary Lee
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [25] The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
    Kazandjian, Dickran
    Mo, Clifton C.
    Landgren, Ola
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (05) : 692 - 703
  • [26] Feasibility of high dose busulfan and melphalan with autologous hematopoietic stem cell transplantation in multiple myeloma.
    Begum, U
    Fitzgerald, D
    Yong, LO
    Grand, M
    Thomas, U
    Chen, Y
    Patel, A
    Goodman, D
    Dillon, C
    Amorosi, E
    Cook, P
    BLOOD, 1997, 90 (10) : 4346 - 4346
  • [27] Single agent thalidomide for treatment of first relapse following high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Hoyer, B
    Fenk, R
    Steidl, U
    Kondakci, M
    Germing, U
    Haas, R
    Kobbe, G
    BLOOD, 2003, 102 (11) : 691A - 692A
  • [28] Second autologous stem cell transplant (ASCT) as salvage therapy for relapsed multiple myeloma.
    Olin, RL
    Porter, DL
    Luger, SM
    Schuster, SJ
    Tsai, D
    Nasta, S
    Perl, A
    Loren, AW
    Goldstein, S
    Glatstein, E
    Siegel, DL
    Vogl, DT
    Mangan, P
    Cunningham, K
    Stadtmauer, EA
    BLOOD, 2005, 106 (11) : 342A - 342A
  • [29] Poor survival of IgD multiple myeloma following high-dose melphalan and autologous stem cell transplantation.
    Jeong, YP
    Kim, S
    Ko, OB
    Koo, JE
    Lee, D
    Suh, C
    BLOOD, 2005, 106 (11) : 373B - 373B
  • [30] MODELING THROMBOCYTOPENIA AS A PREDICTOR OF OUTCOMES FOLLOWING SINGLE, HIGH--DOSE MELPHALAN AND STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.
    Irby, D.
    Cottini, F.
    Hade, E.
    Hofmeister, C.
    Phelps, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S27 - S27
12345